The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.

The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival ...

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem ...

MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This trend is a direct reflection of the continued demand from the medical community for MaaT Pharma’s drug candidate MaaT013. Nomination of Eric Soyer as Chief Financial Officer and transition ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

This trend is a direct reflection of the continued demand from the medical community for MaaT Pharma’s drug candidate MaaT013. Nomination of Eric Soyer as Chief Financial Officer and transition of ...